Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06042582
Other study ID # Algae4IBD
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date November 1, 2023
Est. completion date May 1, 2026

Study information

Verified date September 2023
Source IRCCS San Raffaele
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is part of the project funded by the Horizon2020 program for establishing the consortium Algae4IBD (https://algae4ibd.eu/), where OSR participates as a partner. It aims to promote the implementation of the European Crohn's and Colitis Organization (ECCO/FECCO) Directive and the benefit of the Inflammatory Bowel Disease (IBD) patient's wellness by finding innovative algae based novel small molecule therapeutics. A systemic approach to eco-innovation is adopted to create interconnections between sectors, value chains, natural resources, and relevant societal stewards. To this end, the consortium has set specific objectives to achieve holistic innovations, including technical, economic, health, and social factors that all work in concert. IBD included Crohn's disease and ulcerative colitis. It is a class of chronic inflammatory disorders with complex pathogenesis. Despite the lack of a full understanding of its etiogenesis, many anti-inflammatory treatments have been developed over the last decades. However, not all patients may benefit from these treatments and some of them are refractory to the current therapies or experience relapse of the disease. Therefore, there is still an urgent need to find an innovative line of interventions for ameliorating these patients' overall quality of life. Algae4IBD consortium will form a bridge between innovation and market demands to prevent and treat inflammation, pain, and IBD. Bioactive molecule/compounds extracts from microalgae, cyanobacteria, and macro-algae (MiaCyMa) are an inexhaustible untapped natural source for products destined for IBD prevention and treatment (inflammation, pain, and the disease process associated with the gut's microbiome). The natural source potential is still more promising when considering extremophile strains for excellent metabolism systems. Moreover, the production of the natural source of biological materials should be sustainable. Indeed, the non-genetically modified organisms (GMO cultures offer numerous advantages such as reduced requirements of fresh water and land (no arable land is required), drastic reduction of nitrogen sources, and potential environmental threats. Algae4IBD concept will include a multi-step screening approach and feedback loops across the project steps to achieve its goals. Specifically, OSR is in charge with work package (WP) 4, task 4.4, which aims to characterize the activity of plant cell (algae) extracts named in this proposal as "natural compounds" of algae provided by the consortium in ex-vivo models, using bioptic samples derived from patients with IBD (patients with ulcerative colitis (UC) and Crohn's disease (CD)), comparing them to samples derived from patients without UC and CD.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date May 1, 2026
Est. primary completion date May 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility INCLUSION CRITERIA SUBJECTS WITH THE DIAGNOSIS OF UC OR CD: - subjects undergoing endoscopy and biopsies collection per standard of care - adult patients =18 and <60 years Additionally, for people with UC: - clinical and endoscopic evaluation (Mayo score=2) Additionally, for individuals with CD: - clinical and endoscopic evaluation (Harvey-Bradshaw score =5 and overall simplified endoscopic score (SES-CD) >2) SUBJECTS NOT AFFECTED BY UC OR CD: - subjects undergoing endoscopy and biopsies collection (=18 and <60 years) according to the normal clinical practice (as patients undergoing cancer surveillance, irritable bowel syndrome (IBS), diarrhea) - subjects not affected by UC or CD according to the previously reported clinical and endoscopic evaluation criteria All patients will sign the informed consent. EXCLUSION CRITERIA SUBJECTS WITH THE DIAGNOSIS OF UC OR CD: - subjects with UC or CD who do not have the previously described clinical and endoscopic evaluation criteria SUBJECTS NOT AFFECTED BY UC OR CD (CONTROL GROUP): -subjects undergoing anti-inflammatory and/or immunosuppressive treatments for other diseases not related to UC or CD

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Additional biopsies collection
We will recruit only subjects (UC, CD and NO-UC/CD) scheduled for the endoscopy and biopsies-collection according to the usual clinical practice. During the endoscopy we will collect 6 additional biopsies.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
IRCCS San Raffaele

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the response of intestinal mucosa samples to treatments with natural compounds derived from algae in terms of release of pro-inflammatory factors (1), transcriptomics, metatranscriptomics (2) and lipidomics analysis (3) Release of pro-inflammatory cytokines using ELISA
RNA-Seq-generated FASTQ reads from human colons will be quality filtered and adaptor trimmed with NCBI fastq-dump.
Lipids detected by LC-MS/MS will be classified based on their precursors, and, in parallel, based on their metabolic pathways.
By multi-omic factor analysis we will integrate these data with the patients' clinical parameters, correlating among each other in parallel and giving one single output (outcome measure, in our case, multiomic factor) explaining how the different omic layers are assigned simultaneously to specific clinical characteristics, thus resulting as associated with, or predictive of, the clinical progression of IBD.
30 months
See also
  Status Clinical Trial Phase
Withdrawn NCT04269720 - Biofeedback in Pediatric Inflammatory Bowel Disease N/A
Recruiting NCT04457934 - Effectiveness of PLENVU in the General Screening Population and Patients With IBD
Completed NCT01369355 - A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) Phase 3
Recruiting NCT06146816 - The Assessment of Infrared Treatment for Crohn's Disease N/A
Recruiting NCT05624801 - Cholecalciferol in Chronic Inflammatory Bowel Diseases Phase 3
Recruiting NCT05086562 - Prevalence of Chronic Abdominal Pain in Migraneurs
Recruiting NCT03935451 - Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease Early Phase 1
Recruiting NCT05578768 - Prediction of IBD Disease Activity in Individual Patients Based on PROMs and Clinical Data
Completed NCT01653054 - Anal Dysplasia in Patients With Inflammatory Bowel Disease N/A
Completed NCT04131504 - Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)
Recruiting NCT03952364 - The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States
Enrolling by invitation NCT05414955 - Boom-IBD Clinical Trial N/A
Enrolling by invitation NCT04094324 - Mental Health in Children and Youth Within Pediatric Care
Suspended NCT04225819 - Adjunctive Treatment With Vitamin D3 in Patients With Active IBD N/A
Recruiting NCT03366090 - Immunological Profiles in Inflammatory Bowel Disease N/A
Completed NCT03750565 - Multiple Dose Ethnobridging PK Study in Healthy Subjects Phase 1
Recruiting NCT02970149 - Identifying a Sleep Screener for Disease Relapse in Children With Inflammatory Bowel Disease N/A
Completed NCT02622139 - Multispectral Optoacoustic Tomography (MSOT) for the Evaluation of Disease Activity in Inflammatory Bowel Diseases (IBD) N/A
Completed NCT02364973 - Combined PET-MRI in the Diagnostics of Chronic Inflammatory Bowel Diseases (IBD)- a Feasibility Study
Not yet recruiting NCT06090045 - Airway Involvement In Inflammatory Bowel Disease